Before Pfizer buyout, Hospira links with Pfenex for Lucentis biosimilar
This article was originally published in Scrip
Hospira and Pfenex have agreed to co-develop PF582, a biosimilar for Lucentis (ranibizumab) – a blockbuster treatment for wet age-related macular degeneration (AMD) and other ophthalmic indications – less than a week after Pfizer said it would buy Hospira for $17bn.
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.